| Code | CSB-RA023986MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to reference antibody G201702, designed to specifically target TNFSF11, also known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). TNFSF11 is a critical cytokine member of the tumor necrosis factor superfamily that plays an essential role in bone metabolism by regulating osteoclast differentiation, activation, and survival. This protein is primarily expressed by osteoblasts and activated T cells, and its interaction with the RANK receptor triggers signaling cascades that promote bone resorption. Dysregulation of TNFSF11 is implicated in various pathological conditions including osteoporosis, rheumatoid arthritis, bone metastases, and multiple myeloma-associated bone disease.
The reference antibody G201702 has been utilized in research investigating bone homeostasis, inflammatory bone disorders, and cancer-related skeletal complications. This biosimilar provides researchers with a reliable tool for studying TNFSF11-mediated signaling pathways, evaluating bone remodeling mechanisms, and exploring potential therapeutic interventions for metabolic bone diseases and skeletal malignancies.
There are currently no reviews for this product.